CD5L

Across TCGA pan-cancer cohorts, CD5L mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CD5L data layer compared with 17 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD5L mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CD5L expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

PDAC, LUAD, and GBM are the cancer types where CD5L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.392	1.000	.006	13	view →
LUAD	OS	Tertile	III,IV	0.199	0.721	.012	12	view →
GBM	DFS	Median	All	0.511	0.247	.003	8	view →
COAD	DFS	Tertile	All	0.913	1.000	.045	6	view →
UCEC	DFS	Tertile	All	0.842	0.984	.016	6	view →
CCRCC	DFS	Quartile	III,IV	1.000	0.742	.044	2	view →
LSCC	DFS	Quartile	II,III,IV	0.783	1.000	.047	1	view →
HNSC	DFS	Tertile	III,IV	1.000	0.919	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CD5L–PDAC (OS)

Open the PDAC breakdown →